Mizuho suggests buying Corbus Pharmaceutical’s (NASDAQ:CRBP) after the company plunged almost 60% on Friday following Novo Nordisk’s (NVO) obesity drug data from its mid-stage study, which were below Street expectations.

Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. After 16 weeks of treatment,

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.

Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to its trial results, it has some pretty freaky side effects. As Fierce Biotech reports,

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.

Novo Nordisk (NVO) is down ~6% in Friday trading after reporting phase 2b data on weight loss candidate monlunabant that seemed to underwhelm investors. The 16-week trial examined three dosage strengths of the oral cannabinoid receptor 1 (CB1) inverse agonist,